OVID insider buying and SEC filings, explained
Ovid Therapeutics Inc. · CIK 1636651
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$29K
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Feb 23, 2026 | Sale | Margaret A. Alexander (CEO and Director) sold 11,656 shares at about $1.45 ($17K). Holdings down 16% to 61,750 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 2, 2026 |
| Feb 23, 2026 | Sale | Jeffrey A Rona (Cbfo) sold 8,541 shares at about $1.45 ($12K). Holdings down 9% to 88,188 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 2, 2026 |
| Dec 11, 2025 | Other purchase | Jeremy M. Levin (CEO and Director) bought 82,904 shares in 3 share classes; the filing does not report a price. New position of 47,333 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 18, 2025 |
17 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow OVID in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.